Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.18B), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.85 (market cap $8.29B). The key difference: Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) is the larger of the two by market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays a 4.82% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 3 Days on average.
| INDV | UGP | |
|---|---|---|
Market Cap | $4.18B | $8.29B |
Volume | 1,819,746 | 3,910,942 |
Sector | Health | Energy |
52-Week High | $41.83 | $7.90 |
52-Week Low | $24.09 | $3.63 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $4.47B | $10.36B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UGP trades at $7.79, down 1.27% today but near recent 52-week highs. The stock shows strong technical momentum with bullish moving averages and solid fundamentals including 20.32% ROE and attractive valuation metrics (P/E 11.86, EV/EBITDA 5.1). Recent earnings beat expectations in Q2 2026 with $0.28 EPS versus $0.27 expected. The company demonstrated strong cash flow generation with $5.45B from operations in 2025, supporting its growth investments and financial discipline strategy outlined at recent investor events.
UGP presents a compelling value opportunity with improving profitability margins and revenue growth projected to reach $153.3B in 2026. However, risks include competitive pressures in oil and gas distribution, margin compression from rising costs, and dependence on energy price stability. Analyst consensus remains cautiously optimistic with 36% buy ratings but a $6.85 price target below current levels, suggesting potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →
